Form 4: Adam Joseph Rosenberg Acquires 10,000 Stock Options in Eliem Therapeutics, Inc.

Director Adam Joseph Rosenberg acquired 10,000 stock options in Eliem Therapeutics, Inc. on June 26, 2024.

Summary

• Adam Joseph Rosenberg, a director of Eliem Therapeutics, Inc., filed a Form 4 on June 28, 2024.
• The filing reports a transaction that occurred on June 26, 2024, where Rosenberg acquired 10,000 stock options.
• The exercise price of these options is $7.89.
• The options vest on the earlier of June 26, 2025, or the day before the next annual meeting of stockholders, contingent upon continuous service.
• The options expire on June 25, 2034.
• Following the transaction, Rosenberg directly owns 10,000 derivative securities (stock options).

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing, indicating a standard transaction. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The acquisition of stock options by a director can be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.

Key Dates